PR Newswire·Nov 12, 2026, 6:30 AM ET

DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction

Third quarter 2026 revenue increased 6% year-over-year to $5.3 million.
GAAP gross margin was 59%, while non-GAAP B2B2C gross margin remained at approximately 80% for the 11th consecutive quarter.
Revenue is expected to accelerate at the end of 2026 into 2027 driven by ARR conversion from new enterprise customers.
DarioHealth is expanding payer relationships to include integrated clinical care, medication management, and GLP-1 therapy delivery.
The company signed one of New Jersey's largest health plans, covering 1.5 million lives, through the Amwell channel partnership.
Operating expenses declined 10% year-over-year, resulting in a 15% reduction in operating loss.
Cash, cash equivalents, and short-term deposits totaled $31.2 million as of September 30, 2026.
Over 180 accounts are signed with contracted and late-stage ARR of $13.1 million, with more than 80% related to multi-condition opportunities.
The company launched Dario Women™ for menopause/perimenopause and Dario Sleep for obstructive sleep apnea to expand its multi-condition platform.
DarioIQ, an AI system, is deployed organization-wide and contributed to a 10% year-over-year reduction in operating expenses.
Third quarter net loss was $8.8 million, a decrease from $10.5 million in the same period in 2025.
For the nine months ended September 30, 2026, revenue was $16.1 million, a decrease from $17.1 million in the prior year period.
A conference call to discuss results is scheduled for November 12, 2026, at 8:30 am ET.